ASTER DM HEALTHCARE BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Aster DM Healthcare's preliminary BCG Matrix shows a mix of regional Stars in specialty hospitals and Question Marks in newer international clinics, while legacy units act as steady Cash Cows funding expansion-spotting inefficiencies and growth levers quickly. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a strategic roadmap to optimize capital allocation and scale profitable services.
Stars
Karnataka and Maharashtra Hospital Clusters
Karnataka and Maharashtra hospital clusters are Aster DM Healthcare's growth engines, posting 28-33% YoY revenue growth in FY2025 and driving consolidated margins. Operating EBITDA margins have expanded toward 23% in these clusters, reflecting high market share in fast-growing urban corridors. The company is directing INR 2,600 crore capex into these markets-notably the 500‑bed Yeshwanthpur facility and Whitefield expansions-to capture premium self‑pay and insurance segments.
Aster Labs and Diagnostic Services
Aster Labs and Diagnostic Services has moved to a Star in Aster DM Healthcare's BCG Matrix, posting 17% revenue growth in FY2025 and reaching EBITDA breakeven in Q4 2024; revenues for the diagnostics arm were approximately ₹1,020 crore in FY2025. Operating 260+ labs and patient experience centers, it rides India's diagnostic market growing ~12-15% annually toward organized, branded players. The segment supplies a steady referral funnel to Aster's hospitals while sustaining higher-margin growth, with segment EBITDA margins improving to mid-single digits in FY2025.
Oncology and High-Acuity Specialty Care
Aster DM Healthcare's pivot to Centers of Excellence drove oncology revenues up 27% in FY2025 to INR 1,620 crore, lifting ARPOB above INR 50,000 (a 14% rise year-over-year) by treating higher-complexity cases.
These specialized oncology and high-acuity services grabbed market share as India's non-communicable disease burden rose-cancer DALYs up ~20% since 2015-positioning Aster as a Star in the BCG matrix.
Medical Value Travel (MVT)
The Medical Value Travel (MVT) segment in Aster DM Healthcare's Kerala cluster grew 41% in FY2025, driven by focused international patient acquisition after corporate separation; revenues reached INR 1,250 crore and EBITDA margins ~28%, marking it a Star with high growth and high margins as India gains share in affordable complex surgeries.
It needs continued investment in international marketing and concierge services-estimated incremental spend INR 80-100 crore in 2026-to sustain referral flows, but delivers some of the highest portfolio returns and 3‑5 year IRR above 20%.
- Growth FY2025: +41% (Kerala cluster)
- Revenue FY2025: INR 1,250 crore (MVT Kerala)
- EBITDA margin: ~28%
- Required incremental 2026 spend: INR 80-100 crore
- Expected 3-5yr IRR: >20%
Digital Health and 'Aster Health' App
Digital platform is now core to Aster DM Healthcare's omnichannel push, linking e-pharmacy, teleconsults and home care; the Aster Health app drove a 38% YoY rise in digital consultations in FY2025 and 24% of pharmacy revenue.
It burns cash-₹120 crore capex on tech and AI diagnostics in FY2025-but is vital to lock urban under-40 patients and recurring ARPU gains of 18%.
Market share in digital health rose to ~6% India-wide in 2025 as the app became primary patient touchpoint, improving retention and subscription revenue.
- 38% YoY rise in digital consultations (FY2025)
- 24% of pharmacy revenue via app (FY2025)
- ₹120 crore tech/AI capex (FY2025)
- ARPU up 18% among app users (FY2025)
- ~6% national digital-health market share (2025)
FY25: Karnataka/MH & Kerala MVT Drive Double‑Digit Growth; Oncology & Digital Surge
Karnataka/Maharashtra hospitals, Aster Labs, oncology, Kerala MVT and digital are Stars-FY2025 revenues: Karnataka/MH clusters +28-33% YoY; Diagnostics ₹1,020 crore; Oncology ₹1,620 crore; MVT Kerala ₹1,250 crore; Digital consultations +38%; EBITDA margins: clusters ~23%, MVT ~28%.
| Segment | FY2025 Rev (₹cr) | Growth | EBITDA% |
|---|---|---|---|
| Karnataka/MH | - | 28-33% | ~23% |
| Diagnostics | 1,020 | 17% | mid‑single% |
| Oncology | 1,620 | 27% | - |
| MVT Kerala | 1,250 | 41% | ~28% |
| Digital | - | 38% consults | - |
What is included in the product
Detailed Word Document
Comprehensive BCG review of Aster DM Healthcare's units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing each Aster DM Healthcare business unit in a BCG quadrant for quick strategic clarity.
Cash Cows
Kerala Hospital Cluster (Mature Units)
The Kerala Hospital Cluster remains Aster DM Healthcare's cash cow, holding dominant market share and sustaining margins above 25% for units >6 years.
After a seasonal dip in early 2025, the cluster rebounded to record quarterly revenues of INR 620 crore by Q4 2025, driving operating cash flow.
These profits fund aggressive greenfield projects across Northern and Central India, supporting capex of ~INR 450-500 crore planned for 2026.
Aster Pharmacy (Retail and Franchise)
Aster DM Healthcare's Aster Pharmacy runs 200+ stores and shifted to an asset-light franchise model, boosting cash extraction while keeping capex minimal; pharmacy revenue in FY2025 was ₹1,250 crore, providing steady cash flow despite low single-digit growth.
It functions as a low-growth, high-volume cash cow, generating consistent working capital-pharmacy EBITDA margin rose to 12.5% in 2025 after exiting low-margin wholesale, improving annual EBITDA by ~₹ eighty crore versus 2024.
Mother and Child Specialized Facilities
Mother and Child blocks like Whitefield run >60% occupancy and generated ~INR 320 million revenue in FY2025 for Aster DM Healthcare, needing minimal promo spend due to strong brand loyalty and 78% insurance admission rates.
Andhra Pradesh and Telangana Clusters
Andhra Pradesh and Telangana clusters became Cash Cows as FY25 EBITDA rose 45% to INR 60 crore, driven by steady double-digit revenue growth and a 460 bps occupancy uplift versus FY24.
These mature markets now deliver predictable free cash flow, supporting Aster DM Healthcare's Southern India network and funding expansion elsewhere.
- FY25 EBITDA: INR 60 crore
- EBITDA growth FY24-FY25: +45%
- Occupancy improvement: +460 bps
- Growth profile: steady double-digit revenue increase
Legacy Quaternary Care Services (Transplants)
Aster DM Healthcare's legacy quaternary transplant units in Kochi and Bengaluru generate high-margin revenue with ~25-30% EBITDA margins and ~₹1.2-1.5 billion annual cash inflows in FY2025 from domestic and international referrals, needing low capex while sustaining referral volume growth of ~6% YoY.
The segment is a mature niche and market leader-high clinical expertise, accreditation, and organ program scale create a moat that competitors cannot replicate quickly, preserving strong free cash flow.
- High-margin EBITDA: ~25-30%
- FY2025 cash inflow: ₹1.2-1.5 billion
- Referral growth: ~6% YoY
- Low incremental capex; strong free cash flow
- Durable clinical moat (Kochi, Bengaluru)
Kerala, transplants & pharmacy: FY25 cash cows-EBITDA ₹520-560cr, FCF ₹420-460cr
Kerala cluster, quaternary transplant units and pharmacy are Cash Cows-FY2025 combined EBITDA ~INR 520-560 crore, free cash flow ~INR 420-460 crore, pharmacy revenue ₹1,250 crore, transplant cash inflow ₹1,200-1,500 million, Andhra/Telangana EBITDA ₹60 crore (FY25, +45%).
| Asset | FY25 Revenue/Inflows | FY25 EBITDA | Notes |
|---|---|---|---|
| Kerala cluster | - | ~₹200-240 crore | Margins >25% |
| Pharmacy | ₹1,250 crore | ~₹156 crore | EBITDA 12.5% |
| Transplant units | ₹1,200-1,500 million | 25-30% margin | Low capex |
| Andhra/Telangana | - | ₹60 crore | EBITDA +45% YoY |
Full Transparency, Always
Aster DM Healthcare BCG Matrix
The file you're previewing on this page is the final Aster DM Healthcare BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders-just a professionally formatted, analysis-ready report built for strategic clarity and presentation-ready use.
ASTER DM HEALTHCARE BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Aster DM Healthcare's preliminary BCG Matrix shows a mix of regional Stars in specialty hospitals and Question Marks in newer international clinics, while legacy units act as steady Cash Cows funding expansion-spotting inefficiencies and growth levers quickly. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a strategic roadmap to optimize capital allocation and scale profitable services.
Stars
Karnataka and Maharashtra Hospital Clusters
Karnataka and Maharashtra hospital clusters are Aster DM Healthcare's growth engines, posting 28-33% YoY revenue growth in FY2025 and driving consolidated margins. Operating EBITDA margins have expanded toward 23% in these clusters, reflecting high market share in fast-growing urban corridors. The company is directing INR 2,600 crore capex into these markets-notably the 500‑bed Yeshwanthpur facility and Whitefield expansions-to capture premium self‑pay and insurance segments.
Aster Labs and Diagnostic Services
Aster Labs and Diagnostic Services has moved to a Star in Aster DM Healthcare's BCG Matrix, posting 17% revenue growth in FY2025 and reaching EBITDA breakeven in Q4 2024; revenues for the diagnostics arm were approximately ₹1,020 crore in FY2025. Operating 260+ labs and patient experience centers, it rides India's diagnostic market growing ~12-15% annually toward organized, branded players. The segment supplies a steady referral funnel to Aster's hospitals while sustaining higher-margin growth, with segment EBITDA margins improving to mid-single digits in FY2025.
Oncology and High-Acuity Specialty Care
Aster DM Healthcare's pivot to Centers of Excellence drove oncology revenues up 27% in FY2025 to INR 1,620 crore, lifting ARPOB above INR 50,000 (a 14% rise year-over-year) by treating higher-complexity cases.
These specialized oncology and high-acuity services grabbed market share as India's non-communicable disease burden rose-cancer DALYs up ~20% since 2015-positioning Aster as a Star in the BCG matrix.
Medical Value Travel (MVT)
The Medical Value Travel (MVT) segment in Aster DM Healthcare's Kerala cluster grew 41% in FY2025, driven by focused international patient acquisition after corporate separation; revenues reached INR 1,250 crore and EBITDA margins ~28%, marking it a Star with high growth and high margins as India gains share in affordable complex surgeries.
It needs continued investment in international marketing and concierge services-estimated incremental spend INR 80-100 crore in 2026-to sustain referral flows, but delivers some of the highest portfolio returns and 3‑5 year IRR above 20%.
- Growth FY2025: +41% (Kerala cluster)
- Revenue FY2025: INR 1,250 crore (MVT Kerala)
- EBITDA margin: ~28%
- Required incremental 2026 spend: INR 80-100 crore
- Expected 3-5yr IRR: >20%
Digital Health and 'Aster Health' App
Digital platform is now core to Aster DM Healthcare's omnichannel push, linking e-pharmacy, teleconsults and home care; the Aster Health app drove a 38% YoY rise in digital consultations in FY2025 and 24% of pharmacy revenue.
It burns cash-₹120 crore capex on tech and AI diagnostics in FY2025-but is vital to lock urban under-40 patients and recurring ARPU gains of 18%.
Market share in digital health rose to ~6% India-wide in 2025 as the app became primary patient touchpoint, improving retention and subscription revenue.
- 38% YoY rise in digital consultations (FY2025)
- 24% of pharmacy revenue via app (FY2025)
- ₹120 crore tech/AI capex (FY2025)
- ARPU up 18% among app users (FY2025)
- ~6% national digital-health market share (2025)
FY25: Karnataka/MH & Kerala MVT Drive Double‑Digit Growth; Oncology & Digital Surge
Karnataka/Maharashtra hospitals, Aster Labs, oncology, Kerala MVT and digital are Stars-FY2025 revenues: Karnataka/MH clusters +28-33% YoY; Diagnostics ₹1,020 crore; Oncology ₹1,620 crore; MVT Kerala ₹1,250 crore; Digital consultations +38%; EBITDA margins: clusters ~23%, MVT ~28%.
| Segment | FY2025 Rev (₹cr) | Growth | EBITDA% |
|---|---|---|---|
| Karnataka/MH | - | 28-33% | ~23% |
| Diagnostics | 1,020 | 17% | mid‑single% |
| Oncology | 1,620 | 27% | - |
| MVT Kerala | 1,250 | 41% | ~28% |
| Digital | - | 38% consults | - |
What is included in the product
Detailed Word Document
Comprehensive BCG review of Aster DM Healthcare's units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing each Aster DM Healthcare business unit in a BCG quadrant for quick strategic clarity.
Cash Cows
Kerala Hospital Cluster (Mature Units)
The Kerala Hospital Cluster remains Aster DM Healthcare's cash cow, holding dominant market share and sustaining margins above 25% for units >6 years.
After a seasonal dip in early 2025, the cluster rebounded to record quarterly revenues of INR 620 crore by Q4 2025, driving operating cash flow.
These profits fund aggressive greenfield projects across Northern and Central India, supporting capex of ~INR 450-500 crore planned for 2026.
Aster Pharmacy (Retail and Franchise)
Aster DM Healthcare's Aster Pharmacy runs 200+ stores and shifted to an asset-light franchise model, boosting cash extraction while keeping capex minimal; pharmacy revenue in FY2025 was ₹1,250 crore, providing steady cash flow despite low single-digit growth.
It functions as a low-growth, high-volume cash cow, generating consistent working capital-pharmacy EBITDA margin rose to 12.5% in 2025 after exiting low-margin wholesale, improving annual EBITDA by ~₹ eighty crore versus 2024.
Mother and Child Specialized Facilities
Mother and Child blocks like Whitefield run >60% occupancy and generated ~INR 320 million revenue in FY2025 for Aster DM Healthcare, needing minimal promo spend due to strong brand loyalty and 78% insurance admission rates.
Andhra Pradesh and Telangana Clusters
Andhra Pradesh and Telangana clusters became Cash Cows as FY25 EBITDA rose 45% to INR 60 crore, driven by steady double-digit revenue growth and a 460 bps occupancy uplift versus FY24.
These mature markets now deliver predictable free cash flow, supporting Aster DM Healthcare's Southern India network and funding expansion elsewhere.
- FY25 EBITDA: INR 60 crore
- EBITDA growth FY24-FY25: +45%
- Occupancy improvement: +460 bps
- Growth profile: steady double-digit revenue increase
Legacy Quaternary Care Services (Transplants)
Aster DM Healthcare's legacy quaternary transplant units in Kochi and Bengaluru generate high-margin revenue with ~25-30% EBITDA margins and ~₹1.2-1.5 billion annual cash inflows in FY2025 from domestic and international referrals, needing low capex while sustaining referral volume growth of ~6% YoY.
The segment is a mature niche and market leader-high clinical expertise, accreditation, and organ program scale create a moat that competitors cannot replicate quickly, preserving strong free cash flow.
- High-margin EBITDA: ~25-30%
- FY2025 cash inflow: ₹1.2-1.5 billion
- Referral growth: ~6% YoY
- Low incremental capex; strong free cash flow
- Durable clinical moat (Kochi, Bengaluru)
Kerala, transplants & pharmacy: FY25 cash cows-EBITDA ₹520-560cr, FCF ₹420-460cr
Kerala cluster, quaternary transplant units and pharmacy are Cash Cows-FY2025 combined EBITDA ~INR 520-560 crore, free cash flow ~INR 420-460 crore, pharmacy revenue ₹1,250 crore, transplant cash inflow ₹1,200-1,500 million, Andhra/Telangana EBITDA ₹60 crore (FY25, +45%).
| Asset | FY25 Revenue/Inflows | FY25 EBITDA | Notes |
|---|---|---|---|
| Kerala cluster | - | ~₹200-240 crore | Margins >25% |
| Pharmacy | ₹1,250 crore | ~₹156 crore | EBITDA 12.5% |
| Transplant units | ₹1,200-1,500 million | 25-30% margin | Low capex |
| Andhra/Telangana | - | ₹60 crore | EBITDA +45% YoY |
Full Transparency, Always
Aster DM Healthcare BCG Matrix
The file you're previewing on this page is the final Aster DM Healthcare BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders-just a professionally formatted, analysis-ready report built for strategic clarity and presentation-ready use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Aster DM Healthcare's preliminary BCG Matrix shows a mix of regional Stars in specialty hospitals and Question Marks in newer international clinics, while legacy units act as steady Cash Cows funding expansion-spotting inefficiencies and growth levers quickly. Purchase the full BCG Matrix for quadrant-by-quadrant placement, data-driven recommendations, and a strategic roadmap to optimize capital allocation and scale profitable services.
Stars
Karnataka and Maharashtra Hospital Clusters
Karnataka and Maharashtra hospital clusters are Aster DM Healthcare's growth engines, posting 28-33% YoY revenue growth in FY2025 and driving consolidated margins. Operating EBITDA margins have expanded toward 23% in these clusters, reflecting high market share in fast-growing urban corridors. The company is directing INR 2,600 crore capex into these markets-notably the 500‑bed Yeshwanthpur facility and Whitefield expansions-to capture premium self‑pay and insurance segments.
Aster Labs and Diagnostic Services
Aster Labs and Diagnostic Services has moved to a Star in Aster DM Healthcare's BCG Matrix, posting 17% revenue growth in FY2025 and reaching EBITDA breakeven in Q4 2024; revenues for the diagnostics arm were approximately ₹1,020 crore in FY2025. Operating 260+ labs and patient experience centers, it rides India's diagnostic market growing ~12-15% annually toward organized, branded players. The segment supplies a steady referral funnel to Aster's hospitals while sustaining higher-margin growth, with segment EBITDA margins improving to mid-single digits in FY2025.
Oncology and High-Acuity Specialty Care
Aster DM Healthcare's pivot to Centers of Excellence drove oncology revenues up 27% in FY2025 to INR 1,620 crore, lifting ARPOB above INR 50,000 (a 14% rise year-over-year) by treating higher-complexity cases.
These specialized oncology and high-acuity services grabbed market share as India's non-communicable disease burden rose-cancer DALYs up ~20% since 2015-positioning Aster as a Star in the BCG matrix.
Medical Value Travel (MVT)
The Medical Value Travel (MVT) segment in Aster DM Healthcare's Kerala cluster grew 41% in FY2025, driven by focused international patient acquisition after corporate separation; revenues reached INR 1,250 crore and EBITDA margins ~28%, marking it a Star with high growth and high margins as India gains share in affordable complex surgeries.
It needs continued investment in international marketing and concierge services-estimated incremental spend INR 80-100 crore in 2026-to sustain referral flows, but delivers some of the highest portfolio returns and 3‑5 year IRR above 20%.
- Growth FY2025: +41% (Kerala cluster)
- Revenue FY2025: INR 1,250 crore (MVT Kerala)
- EBITDA margin: ~28%
- Required incremental 2026 spend: INR 80-100 crore
- Expected 3-5yr IRR: >20%
Digital Health and 'Aster Health' App
Digital platform is now core to Aster DM Healthcare's omnichannel push, linking e-pharmacy, teleconsults and home care; the Aster Health app drove a 38% YoY rise in digital consultations in FY2025 and 24% of pharmacy revenue.
It burns cash-₹120 crore capex on tech and AI diagnostics in FY2025-but is vital to lock urban under-40 patients and recurring ARPU gains of 18%.
Market share in digital health rose to ~6% India-wide in 2025 as the app became primary patient touchpoint, improving retention and subscription revenue.
- 38% YoY rise in digital consultations (FY2025)
- 24% of pharmacy revenue via app (FY2025)
- ₹120 crore tech/AI capex (FY2025)
- ARPU up 18% among app users (FY2025)
- ~6% national digital-health market share (2025)
FY25: Karnataka/MH & Kerala MVT Drive Double‑Digit Growth; Oncology & Digital Surge
Karnataka/Maharashtra hospitals, Aster Labs, oncology, Kerala MVT and digital are Stars-FY2025 revenues: Karnataka/MH clusters +28-33% YoY; Diagnostics ₹1,020 crore; Oncology ₹1,620 crore; MVT Kerala ₹1,250 crore; Digital consultations +38%; EBITDA margins: clusters ~23%, MVT ~28%.
| Segment | FY2025 Rev (₹cr) | Growth | EBITDA% |
|---|---|---|---|
| Karnataka/MH | - | 28-33% | ~23% |
| Diagnostics | 1,020 | 17% | mid‑single% |
| Oncology | 1,620 | 27% | - |
| MVT Kerala | 1,250 | 41% | ~28% |
| Digital | - | 38% consults | - |
What is included in the product
Detailed Word Document
Comprehensive BCG review of Aster DM Healthcare's units with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page overview placing each Aster DM Healthcare business unit in a BCG quadrant for quick strategic clarity.
Cash Cows
Kerala Hospital Cluster (Mature Units)
The Kerala Hospital Cluster remains Aster DM Healthcare's cash cow, holding dominant market share and sustaining margins above 25% for units >6 years.
After a seasonal dip in early 2025, the cluster rebounded to record quarterly revenues of INR 620 crore by Q4 2025, driving operating cash flow.
These profits fund aggressive greenfield projects across Northern and Central India, supporting capex of ~INR 450-500 crore planned for 2026.
Aster Pharmacy (Retail and Franchise)
Aster DM Healthcare's Aster Pharmacy runs 200+ stores and shifted to an asset-light franchise model, boosting cash extraction while keeping capex minimal; pharmacy revenue in FY2025 was ₹1,250 crore, providing steady cash flow despite low single-digit growth.
It functions as a low-growth, high-volume cash cow, generating consistent working capital-pharmacy EBITDA margin rose to 12.5% in 2025 after exiting low-margin wholesale, improving annual EBITDA by ~₹ eighty crore versus 2024.
Mother and Child Specialized Facilities
Mother and Child blocks like Whitefield run >60% occupancy and generated ~INR 320 million revenue in FY2025 for Aster DM Healthcare, needing minimal promo spend due to strong brand loyalty and 78% insurance admission rates.
Andhra Pradesh and Telangana Clusters
Andhra Pradesh and Telangana clusters became Cash Cows as FY25 EBITDA rose 45% to INR 60 crore, driven by steady double-digit revenue growth and a 460 bps occupancy uplift versus FY24.
These mature markets now deliver predictable free cash flow, supporting Aster DM Healthcare's Southern India network and funding expansion elsewhere.
- FY25 EBITDA: INR 60 crore
- EBITDA growth FY24-FY25: +45%
- Occupancy improvement: +460 bps
- Growth profile: steady double-digit revenue increase
Legacy Quaternary Care Services (Transplants)
Aster DM Healthcare's legacy quaternary transplant units in Kochi and Bengaluru generate high-margin revenue with ~25-30% EBITDA margins and ~₹1.2-1.5 billion annual cash inflows in FY2025 from domestic and international referrals, needing low capex while sustaining referral volume growth of ~6% YoY.
The segment is a mature niche and market leader-high clinical expertise, accreditation, and organ program scale create a moat that competitors cannot replicate quickly, preserving strong free cash flow.
- High-margin EBITDA: ~25-30%
- FY2025 cash inflow: ₹1.2-1.5 billion
- Referral growth: ~6% YoY
- Low incremental capex; strong free cash flow
- Durable clinical moat (Kochi, Bengaluru)
Kerala, transplants & pharmacy: FY25 cash cows-EBITDA ₹520-560cr, FCF ₹420-460cr
Kerala cluster, quaternary transplant units and pharmacy are Cash Cows-FY2025 combined EBITDA ~INR 520-560 crore, free cash flow ~INR 420-460 crore, pharmacy revenue ₹1,250 crore, transplant cash inflow ₹1,200-1,500 million, Andhra/Telangana EBITDA ₹60 crore (FY25, +45%).
| Asset | FY25 Revenue/Inflows | FY25 EBITDA | Notes |
|---|---|---|---|
| Kerala cluster | - | ~₹200-240 crore | Margins >25% |
| Pharmacy | ₹1,250 crore | ~₹156 crore | EBITDA 12.5% |
| Transplant units | ₹1,200-1,500 million | 25-30% margin | Low capex |
| Andhra/Telangana | - | ₹60 crore | EBITDA +45% YoY |
Full Transparency, Always
Aster DM Healthcare BCG Matrix
The file you're previewing on this page is the final Aster DM Healthcare BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders-just a professionally formatted, analysis-ready report built for strategic clarity and presentation-ready use.
